PedAM
Pediatric Disease Annotations & Medicines
| fecal incontinence | ||||
| Disease ID | 1927 |
|---|---|
| Disease | fecal incontinence |
| Definition | Failure of voluntary control of the anal sphincters, with involuntary passage of feces and flatus. |
| Synonym | [d]incontinence of faeces [d]incontinence of faeces (situation) [d]incontinence of faeces nos [d]incontinence of faeces nos (situation) [d]incontinence of feces [d]incontinence of feces (context-dependent category) [d]incontinence of feces (situation) [d]incontinence of feces nos [d]incontinence of feces nos (context-dependent category) [d]incontinence of feces nos (situation) alteration in bowel elimination: incontinence anal incontinence bowel incontinena bowel incontinence bowel incontinent bowels: incontinent faecal incontinence fecal incontinence [disease/finding] fecal incontinence nos fecal incontinences feces incontinence feces incontinence of foecal incontinence incontinence bowel incontinence faecal incontinence fecal incontinence of bowel incontinence of faeces incontinence of faeces (finding) incontinence of feces incontinence of feces (finding) incontinence of stool incontinence stool incontinence, fecal incontinence-faeces-sym incontinence-feces-sym incontinences, fecal incontinent bowel incontinent of bowels incontinent of faeces incontinent of faeces (& symptom) incontinent of faeces (& symptom) (finding) incontinent of faeces - finding incontinent of faeces symptom incontinent of feces incontinent of feces (& symptom) incontinent of feces (finding) incontinent of feces - finding incontinent of feces symptom incontinent of stool involuntary stool loss of bowel control of bowel incontinence stool incontinence stool soiling stools.incontinent |
| UMLS | C0015732 |
| MeSH | |
| SNOMED-CT | |
| Comorbidity | UMLS | Disease | Sentences' Count(Total Sentences:27) C0009806 | constipation | 7 C0034888 | rectal prolapse | 5 C0442874 | neuropathy | 3 C0042870 | vitamin d deficiency | 2 C0080178 | spina bifida | 2 C0021831 | bowel disease | 2 C0042870 | vitamin d defic | 2 C0497327 | dementia | 2 C0021390 | inflammatory bowel disease | 2 C0028754 | obesity | 2 C0259749 | autonomic neuropathy | 1 C0027868 | neuromuscular disease | 1 C0027765 | neurological disorders | 1 C0019569 | hirschsprung's disease | 1 C0026848 | muscular disorders | 1 C0042075 | urological disorders | 1 C0027868 | neuromuscular disorders | 1 C0027765 | neurological disorder | 1 C0030567 | parkinson's disease | 1 C0009806 | constipated | 1 C0004134 | ataxia | 1 C0026848 | muscular diseases | 1 C0011991 | diarrhea | 1 C0027868 | neuromuscular diseases | 1 C0033953 | sexual dysfunction | 1 C0011847 | diabetes | 1 C0458219 | complex regional pain syndrome | 1 |
| Curated Gene | (Waiting for update.) |
| Inferring Gene | (Waiting for update.) |
| Text Mined Gene | (Waiting for update.) |
| Locus | (Waiting for update.) |
| Disease ID | 1927 |
|---|---|
| Disease | fecal incontinence |
| Integrated Phenotype | (Waiting for update.) |
| Text Mined Phenotype | HPO | Name | Sentences' Count(Total Phenotypes:21) HP:0002019 | Dyschezia | 7 HP:0002035 | Rectal prolapse | 5 HP:0012531 | Pain | 3 HP:0002414 | Spina bifida | 2 HP:0001513 | Obesity | 2 HP:0000726 | Dementia | 2 HP:0100512 | Vitamin D deficiency | 2 HP:0002014 | Diarrhea | 1 HP:0012735 | Coughing | 1 HP:0002385 | Paraparesis | 1 HP:0002573 | Bloody diarrhea | 1 HP:0002070 | Appendicular ataxia | 1 HP:0001324 | Muscular weakness | 1 HP:0001251 | Ataxia | 1 HP:0001297 | Cerebral vascular events | 1 HP:0100548 | Exstrophy | 1 HP:0100822 | Rectocele | 1 HP:0002836 | Bladder exstrophy | 1 HP:0100543 | Cognitive deficits | 1 HP:0000020 | Bladder incontinence | 1 HP:0002028 | Chronic diarrhea | 1 |
| Disease ID | 1927 |
|---|---|
| Disease | fecal incontinence |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:4) C0009806 | constipation | 7 C0034888 | rectal prolapse | 5 C0442874 | neuropathy | 3 C0234131 | motor dysfunction | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:8) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0015732 | bupivacaine | D002045 | 2180-92-9 | fecal incontinence | MESH:D005242 | marker/mechanism | 11685017 | ||
| C0015732 | ceftazidime | D002442 | 78439-06-2 | fecal incontinence | MESH:D005242 | marker/mechanism | 17325906 | ||
| C0015732 | chlorpromazine | D002746 | 50-53-3 | fecal incontinence | MESH:D005242 | marker/mechanism | 4247303 | ||
| C0015732 | clozapine | D003024 | 5786-21-0 | fecal incontinence | MESH:D005242 | marker/mechanism | 18174637 | ||
| C0015732 | morphine | D009020 | 57-27-2 | fecal incontinence | MESH:D005242 | marker/mechanism | 16971632 | ||
| C0015732 | olanzapine | C076029 | 132539-06-1 | fecal incontinence | MESH:D005242 | marker/mechanism | 12716282 | ||
| C0015732 | prazosin | D011224 | 19216-56-9 | fecal incontinence | MESH:D005242 | marker/mechanism | 1975868 | ||
| C0015732 | vincristine | D014750 | - | fecal incontinence | MESH:D005242 | therapeutic | 9375755 | ||
FDA approved drug and dosage information(Total Drugs:4) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D005242 | zyprexa | olanzapine | 2.5MG | TABLET;ORAL | Prescription | AB | Yes | No |
| MESH:D005242 | zyprexa | olanzapine | 10MG/VIAL | INJECTABLE;INTRAMUSCULAR | Prescription | AP | Yes | Yes |
| MESH:D005242 | zyprexa | olanzapine | 2.5MG | TABLET;ORAL | Prescription | AB | Yes | No |
| MESH:D005242 | zyprexa | olanzapine | 10MG/VIAL | INJECTABLE;INTRAMUSCULAR | Prescription | AP | Yes | Yes |
FDA labeling changes(Total Drugs:4) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D005242 | 08/14/2008 | zyprexa | olanzapine | schizophrenia; bipolar disorder | Safety and effectiveness have not been established for patients less than 18 years of age In an analysis of placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with schizophrenia or bipolar disorder, olanzapine was associated with: oHyperglycemia - a statistically significantly greater mean change in fasting glucose levels compared to placebo oHyperlipidemia statistically significant increases compared to placebo in fasting triglycerides, fasting total cholesterol and fasting LDL cholesterol oWeight gain olanzapine treated patients gained an average of 4.6 kg, compared to an average of 0.3 kg in placebo-treated patients with a median exposure of 3 weeks; Average weight gain during long-term therapy was 7.4 kg | - | B | - | - | - | Lilly | 10/1/2007 | FALSE' |
| MESH:D005242 | 08/14/2008 | zyprexa | olanzapine | schizophrenia; bipolar disorder | Safety and effectiveness have not been established for patients less than 18 years of age In an analysis of placebo-controlled olanzapine monotherapy studies of adolescent patients, including those with schizophrenia or bipolar disorder, olanzapine was associated with: oHyperglycemia - a statistically significantly greater mean change in fasting glucose levels compared to placebo oHyperlipidemia statistically significant increases compared to placebo in fasting triglycerides, fasting total cholesterol and fasting LDL cholesterol oWeight gain olanzapine treated patients gained an average of 4.6 kg, compared to an average of 0.3 kg in placebo-treated patients with a median exposure of 3 weeks; Average weight gain during long-term therapy was 7.4 kg | - | B | - | - | - | Lilly | 10/1/2007 | FALSE' |
| MESH:D005242 | 4/12/2009 | zyprexa | olanzapine | Treatment of manic or mixed episodes of bipolar I disorder and schizophrenia in adolescents ages 13-17 | Extended schizophrenia and manic or mixed episodes of bipolar I disorder indications from adults to adolescents 1317 years of age Safety and effectiveness in children < 13 years of age have not been established Recommended starting dose for adolescents is lower than that for adults Compared to patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total cholesterol, triglycerides, LDL cholesterol, prolactin and hepatic transaminase levels Information on dosing, adverse reactions, pharmacokinetics, clinical studies | Labeling | B | - | - | - | Lilly | 10/1/2007 | TRUE' |
| MESH:D005242 | 4/12/2009 | zyprexa | olanzapine | Treatment of manic or mixed episodes of bipolar I disorder and schizophrenia in adolescents ages 13-17 | Extended schizophrenia and manic or mixed episodes of bipolar I disorder indications from adults to adolescents 1317 years of age Safety and effectiveness in children < 13 years of age have not been established Recommended starting dose for adolescents is lower than that for adults Compared to patients from adult clinical trials, adolescents were likely to gain more weight, experience increased sedation, and have greater increases in total cholesterol, triglycerides, LDL cholesterol, prolactin and hepatic transaminase levels Information on dosing, adverse reactions, pharmacokinetics, clinical studies | Labeling | B | - | - | - | Lilly | 10/1/2007 | TRUE' |